OralParenteralTopicalTherapeutic flag
Cosmetic cross-reference
Theophylline Anhydrous
CAS 58-55-9
Theophylline Anhydrous (CAS 58-55-9) is a Phase 4 pharmaceutical compound with 15 bioactivity targets and 728 adverse event associations.
SOURCE
NLM DailyMed
Label records
0
SOURCE
EMBL-EBI ChEMBL
Bioactivity
22
SOURCE
DrugCentral
Adverse signals
728
SOURCE
IUPHAR/BPS
PubMed IDs
14
SOURCE
EMBL-EBI ChEMBL
B25820EEF0F0
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Primary Name
Theophylline Anhydrous
CAS Number
58-55-9
UNII
0I55128JYK
InChIKey
ZFXYFBGIUFBOJW-UHFFFAOYSA-N
ChEMBL ID
CHEMBL190
Molecule Type
Protein
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
Synonyms and normalized names
THEOPHYLLINETheo-24Elixophyllin
natural productoralparenteraltherapeutic flagtopical
SOURCE
EMBL-EBI ChEMBL
B25820EEF0F0
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Phase 4 (Approved)
Approved or marketed human pharmaceutical use is represented in the source phase field.
ChEMBL CHEMBL190 | Protein
SOURCE
Ingredients table / CosIng profile
same-CAS cross-reference
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
SOURCE
EMBL-EBI ChEMBL
22 bioactivity rows
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | IC50 | 280 nM | 1 | - |
| Adenosine receptor A2a GPCR |
Ki | 9.22 | - | Homo sapiens |
| cGMP-inhibited 3',5'-cyclic phosphodiesterase A Enzyme |
Ki | 3.85 | - | Homo sapiens |
| Adenosine receptor A1 GPCR |
Ki | 9.22 | - | Homo sapiens |
| Adenosine receptor A2b GPCR |
Ki | 5.57 | - | Homo sapiens |
| Adenosine receptor A3 GPCR |
Ki | 7.85 | - | Homo sapiens |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4A Enzyme |
Ki | 4.11 | - | Homo sapiens |
| Alkaline phosphatase, tissue-nonspecific isozyme Enzyme |
Ki | 4.09 | - | Homo sapiens |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Kinase |
IC50 | 4.12 | - | Homo sapiens |
| Adenosine receptor A1 GPCR |
Ki | 6.15 | - | Rattus norvegicus |
| Adenosine receptor A2a GPCR |
Ki | 5.17 | - | Rattus norvegicus |
| Uncharacterized protein Enzyme |
Ki | 4.11 | - | Bos taurus |
| Adenosine receptor A3 GPCR |
Ki | 4.07 | - | Rattus norvegicus |
| Adenosine receptor A1 GPCR |
Ki | 5.42 | - | Bos taurus |
| Adenosine receptor A1 GPCR |
Ki | 5.01 | - | Cavia porcellus |
| Adenosine A2 receptor GPCR |
Ki | 5.88 | - | Rattus norvegicus |
| Adenosine A2b receptor GPCR |
Ki | 4.82 | - | Rattus norvegicus |
| Adenosine receptor GPCR |
Ki | 4.7 | - | Rattus norvegicus |
| Heart phosphodiesterase Enzyme |
IC50 | 4.04 | - | Bos taurus |
| Adenosine A2a receptor GPCR |
Ki | 4.89 | - | Cavia porcellus |
| Adenosine receptor A2b GPCR |
Ki | 5.25 | - | Mus musculus |
| Transmembrane domain-containing protein TMIGD3 Unclassified |
Ki | 4.06 | - | Homo sapiens |
SOURCE
DrugCentral
80 associations
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Asthma | 923 | 1368.238 | 10003553 |
| Wheezing | 677 | 935.398 | 10047924 |
| Chronic obstructive pulmonary disease | 395 | 449.27 | 10009033 |
| Dyspnoea | 1284 | 416.465 | 10013968 |
| Productive cough | 356 | 388.315 | 10036790 |
| Obstructive airways disorder | 214 | 333.246 | 10061877 |
| Forced expiratory volume decreased | 117 | 282.052 | 10016987 |
| Cough | 622 | 240.763 | 10011224 |
| Sputum discoloured | 149 | 235.201 | 10041807 |
| Sleep disorder due to a general medical condition | 135 | 229.66 | 10063910 |
| Right atrial hypertrophy | 59 | 227.304 | 10057501 |
| Full blood count abnormal | 183 | 202.816 | 10017412 |
| Bronchial wall thickening | 64 | 176.325 | 10067182 |
| Right ventricular hypertrophy | 59 | 169.672 | 10050326 |
| Pulmonary pain | 72 | 169.638 | 10074693 |
| Chest discomfort | 294 | 166.73 | 10008469 |
| Obstruction | 74 | 161.603 | 10061876 |
| Bronchial secretion retention | 63 | 147.966 | 10066820 |
| Pulmonary function test abnormal | 63 | 147.056 | 10061602 |
| Aortic valve stenosis | 67 | 142.832 | 10002918 |
| Hypercapnia | 73 | 130.312 | 10020591 |
| Rales | 100 | 130.19 | 10037833 |
| Breath sounds abnormal | 90 | 128.434 | 10064780 |
| Alopecia | 21 | 122.721 | 10001760 |
| Therapeutic product effect incomplete | 275 | 120.907 | 10082200 |
| Off label use | 271 | 118.094 | 10053762 |
| Nasal oedema | 43 | 115.891 | 10028750 |
| Chest X-ray abnormal | 65 | 113.712 | 10008499 |
| Pneumonia | 739 | 112.687 | 10035664 |
| Sinus tachycardia | 119 | 112.348 | 10040752 |
| Loss of personal independence in daily activities | 223 | 112.227 | 10079487 |
| Bronchial neoplasm | 29 | 110.427 | 10052245 |
| Eosinophil count increased | 85 | 107.485 | 10014945 |
| Bronchial obstruction | 45 | 105.703 | 10006440 |
| Nasal congestion | 172 | 105.325 | 10028735 |
| Dyspnoea exertional | 184 | 105.106 | 10013971 |
| Diastolic dysfunction | 70 | 104.81 | 10052337 |
| Vital capacity decreased | 40 | 104.243 | 10047582 |
| Systemic lupus erythematosus | 3 | 101.943 | 10042945 |
| Heart sounds | 31 | 97.166 | 10069168 |
| Nasal turbinate hypertrophy | 30 | 96.977 | 10028779 |
| Endometrial ablation | 29 | 93.009 | 10051908 |
| Rhinitis perennial | 24 | 92.194 | 10039094 |
| Rhonchi | 45 | 91.323 | 10039109 |
| Prolonged expiration | 32 | 90.795 | 10059411 |
| Benign prostatic hyperplasia | 67 | 90.735 | 10004446 |
| Respiratory failure | 263 | 88.213 | 10038695 |
| Emphysema | 76 | 88.097 | 10014561 |
| Status asthmaticus | 30 | 84.884 | 10041961 |
| Infusion related reaction | 30 | 83.934 | 10051792 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
SOURCE
IUPHAR/BPS
8 interactions
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| A 2A receptor ADORA2A |
Antagonist | 5.170000076293945 pKi | 9459566|16219300|9179373 |
| A 2B receptor ADORA2B |
Antagonist | 4.130000114440918 pKi | 16219300|11705449|12014951|18404493 |
| A 1 receptor ADORA1 |
Antagonist | 4.9 pKi | 7798201|9459566|16219300|11705449 |
| A 1 receptor Adora1 |
Antagonist | 4.85 pKi | 8230124 |
| A 2A receptor Adora2a |
Antagonist | 4.6 pKi | 8230124 |
| A 2B receptor Adora2b |
Antagonist | 5.25 pKi | 19141710 |
| A 3 receptor ADORA3 |
Antagonist | 4.06 pKi | 9459566 |
| A 3 receptor Adora3 |
Antagonist | 4.0 pKi | 8022403|7632796 |
SOURCE
PharmGKB
6 phenotype rows
Pharmacogenomics
Drug-gene phenotype annotations and evidence levels from PharmGKB-mapped rows.
CYP1A2 (PA27093) rs2069514
Genotype GG is associated with increased ratio of 1,3 DMU/theophylline when treated with theophylline in people with Asthma as compared to genotypes AA + AG.
Evidence: -; PMID 16841220
CYP2E1 (PA129) rs2031920
Genotype CC is associated with increased ratio of 1,3 DMU/theophylline when treated with theophylline in people with Asthma as compared to genotype CT.
Evidence: -; PMID 16841220
CYP2E1 (PA129) rs3813867
Genotype GG is associated with increased ratio of 1,3 DMU/theophylline when treated with theophylline in people with Asthma as compared to genotype CG.
Evidence: -; PMID 16841220
CYP1A2 (PA27093) rs2069514
Genotypes AA + AG are associated with decreased metabolism of theophylline in people with Asthma as compared to genotype GG.
Evidence: -; PMID 12732846
CYP1A2 (PA27093) rs35694136
Allele T is associated with decreased plasma drug levels when treated with theophylline in people with Pulmonary Disease, Chronic Obstructive as compared to allele del.
Evidence: -; PMID 20797314
CYP1A2 (PA27093) rs35694136
Genotypes TT + T/del are associated with increased severity of Pulmonary Disease, Chronic Obstructive when treated with theophylline in people with Pulmonary Disease, Chronic Obstructive as compared to genotype del/del.
Evidence: -; PMID 20797314
SOURCE
NLM RxNorm
6 name rows
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| THEOPHYLLINE | 10438 | SU | MTHSPL |
| THEOPHYLLINE ANHYDROUS | 91178 | SU | MTHSPL |
| theophylline | 10438 | IN | RXNORM |
| theophylline anhydrous | 91178 | PIN | RXNORM |
| Theo-24 | 203388 | BN | RXNORM |
| Elixophyllin | 203394 | BN | RXNORM |
SOURCE
SIDER
80 side-effect rows
Side Effects
SIDER side-effect terms mapped to the drug or same-CAS compound identity.
| Side Effect | Drug Name | MedDRA Type | Concept ID |
|---|---|---|---|
| Abdominal pain | theophylline | LLT | C0000737 |
| Abdominal pain | theophylline | PT | C0000737 |
| Abdominal pain upper | theophylline | PT | C0232492 |
| Acute overdose | theophylline | LLT | C1963951 |
| Agitation | theophylline | LLT | C0085631 |
| Agitation | theophylline | PT | C0085631 |
| Albuminuria | theophylline | LLT | C0001925 |
| Albuminuria | theophylline | PT | C0001925 |
| Alopecia | theophylline | LLT | C0002170 |
| Alopecia | theophylline | PT | C0002170 |
| Anaphylactic shock | theophylline | LLT | C0002792 |
| Anaphylactic shock | theophylline | PT | C0002792 |
| Anaphylactic shock | theophylline | PT | C0002792 |
| Anaphylactoid reaction | theophylline | LLT | C0340865 |
| Anaphylactoid reaction | theophylline | PT | C0340865 |
| Anorexia | theophylline | LLT | C0003123 |
| Anxiety | theophylline | LLT | C0003467 |
| Anxiety | theophylline | PT | C0003467 |
| Arrhythmia | theophylline | LLT | C0003811 |
| Arrhythmia | theophylline | PT | C0003811 |
| Atrial fibrillation | theophylline | LLT | C0004238 |
| Atrial fibrillation | theophylline | PT | C0004238 |
| Atrial tachycardia | theophylline | PT | C0546959 |
| Blood uric acid increased | theophylline | PT | C0235416 |
| Body temperature increased | theophylline | LLT | C0015967 |
| Body temperature increased | theophylline | PT | C0015967 |
| Brain injury | theophylline | LLT | C0270611 |
| Brain injury | theophylline | PT | C0270611 |
| Brain injury | theophylline | PT | C0270611 |
| Cardiac flutter | theophylline | LLT | C0016385 |
| Cardiac flutter | theophylline | PT | C0016385 |
| Cardio-respiratory arrest | theophylline | LLT | C0600228 |
| Cardio-respiratory arrest | theophylline | PT | C0600228 |
| Coma | theophylline | LLT | C0009421 |
| Coma | theophylline | PT | C0009421 |
| Convulsion | theophylline | LLT | C0036572 |
| Convulsion | theophylline | PT | C0036572 |
| Convulsion | theophylline | PT | C0036572 |
| Convulsions generalised | theophylline | LLT | C0234533 |
| Decreased appetite | theophylline | PT | C0232462 |
| Dermatitis | theophylline | PT | C0011603 |
| Dermatitis contact | theophylline | LLT | C0011616 |
| Dermatitis contact | theophylline | PT | C0011616 |
| Dermatitis exfoliative | theophylline | LLT | C0011606 |
| Dermatitis exfoliative | theophylline | PT | C0011606 |
| Diarrhoea | theophylline | LLT | C0011991 |
| Diarrhoea | theophylline | PT | C0011991 |
| Disorientation | theophylline | LLT | C0233407 |
| Disorientation | theophylline | PT | C0233407 |
| Diuresis | theophylline | LLT | C0012797 |
| Dizziness | theophylline | LLT | C0012833 |
| Dizziness | theophylline | PT | C0012833 |
| Epigastric discomfort | theophylline | PT | C1291078 |
| Epigastric pain | theophylline | LLT | C0232493 |
| Extrasystoles | theophylline | LLT | C0340464 |
| Extrasystoles | theophylline | PT | C0340464 |
| Extravasation | theophylline | LLT | C0015376 |
| Extravasation | theophylline | PT | C0015376 |
| Fluid overload | theophylline | LLT | C0546817 |
| Fluid overload | theophylline | PT | C0546817 |
| Flushing | theophylline | LLT | C0016382 |
| Flushing | theophylline | PT | C0016382 |
| Gastric irritation | theophylline | LLT | C0392176 |
| Gastrointestinal pain | theophylline | PT | C0687713 |
| Gastrooesophageal reflux disease | theophylline | LLT | C0017168 |
| Gastrooesophageal reflux disease | theophylline | PT | C0017168 |
| Haematemesis | theophylline | LLT | C0018926 |
| Haematemesis | theophylline | PT | C0018926 |
| Haematuria | theophylline | LLT | C0018965 |
| Haematuria | theophylline | PT | C0018965 |
| Haemodynamic instability | theophylline | LLT | C0948268 |
| Haemodynamic instability | theophylline | PT | C0948268 |
| Headache | theophylline | LLT | C0018681 |
| Headache | theophylline | PT | C0018681 |
| Hypercalcaemia | theophylline | LLT | C0020437 |
| Hypercalcaemia | theophylline | PT | C0020437 |
| Hyperglycaemia | theophylline | LLT | C0020456 |
| Hyperglycaemia | theophylline | PT | C0020456 |
| Hypersensitivity | theophylline | LLT | C0020517 |
| Hypersensitivity | theophylline | PT | C0020517 |
SOURCE
Rendered pharma page rows
FAQPage JSON-LD
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Theophylline Anhydrous used for in pharmaceutical contexts?
Theophylline Anhydrous (CAS 58-55-9) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Theophylline Anhydrous?
Theophylline Anhydrous has 728 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Asthma, Wheezing, Chronic obstructive pulmonary disease, Dyspnoea, Productive cough. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Theophylline Anhydrous also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Theophylline with EU status "prohibited".
What clinical phase is Theophylline Anhydrous in?
Theophylline Anhydrous is rendered with ChEMBL max phase 4 (approved).
What bioactivity targets are documented for Theophylline Anhydrous?
Theophylline Anhydrous has 22 bioactivity rows in this page query. Rendered target entries include Adenosine receptor A2a, cGMP-inhibited 3',5'-cyclic phosphodiesterase A, Adenosine receptor A1, Adenosine receptor A2b, Adenosine receptor A3.